BHL Seeks Manufacturing Rights for Baricitinib Following Licensing Refusal by Incyte and Eli Lilly

shot by IP News Shots / 7:07 pm on 28 June, 2021

Bajaj Healthcare Limited (BHL) has approached the Indian Patent Office seeking compulsory license for Baricitinib as potential treatment option for COVID-19.  BHL had first sought a voluntary license for the drug from Incyte Corporation who owns the patent and Eli Lilly and Company, who has the exclusive licensing rights for the drug. Notably, both companies had turned down the voluntary licensing request by BHL.

Industry: Pharmaceuticals

Read more at The Print

Eli Lilly Issues Voluntary Licenses for Baricitinib to Three Indian Drug Companies  

shot by IP News Shots / 10:27 am on 12 May, 2021

Eli Lilly and Company has issued non-exclusive voluntary licenses for its drug Baricitinib, which is used in the treatment of COVID-19, to three Indian pharma companies. The licensing agreement is signed by Eli Lilly with Cipla Limited, Sun Pharmaceutical Industries Ltd. and Lupin Limited. Interestingly, Natco Pharma Limited had filed for a compulsory license (CL) for Baricitinib with the Indian Patent Office earlier and has already begun manufacturing the drug even as the CL proceedings are underway.

Read More at: https://www.business-standard.com/article/companies/eli-lilly-signs-licensing-pact-with-cipla-sun-lupin-for-covid-19-drug-121051100039_1.html

Industry: Pharmaceuticals

Capricor and Johns Hopkins University Sign Exclusive Worldwide Licensing Agreement for Exosome Technology IP

shot by IP News Shots / 3:58 pm on 30 April, 2021

Capricor Therapeutics has licensed exosome technology intellectual property (IP) from Johns Hopkins University with an exclusive worldwide licensing agreement. As per the terms of the licensing agreement, Capricor will have rights to the IP associated with the patent applications that are part of the agreement.

Read More at: https://www.streetinsider.com/dr/news.php?id=18330207&gfv=1

Industry: Biotechnology

WPD Pharmaceuticals and Moleculin Sign Amended Sublicense Agreement

shot by IP News Shots / 7:37 pm on 31 March, 2021

WPD Pharmaceuticals Inc. and Moleculin Biotech Inc. have signed an amended sublicense agreement for the intellectual property rights to the latter’s Annamycin, WP1066 and WP1122 portfolios. As per the terms of the agreement, WPD will pay a sales-based royalty to Moleculin.

Read More at: https://www.einnews.com/pr_news/537775829/wpd-pharmaceuticals-announces-amended-sublicense-agreement-with-moleculin-biotech-for-wp1066-wp1122-and-annamycin-drug-candidates

Industry: Biotechnology, Pharmaceuticals

AuraVax and University of Houston Sign Exclusive IP Licensing Agreement

shot by IP News Shots / 6:09 pm on 04 February, 2021

AuraVax Therapeutics Inc. has signed an exclusive licensing agreement with the University of Houston for intellectual property relating to a new intranasal vaccine and STING agonist technologies. The intranasal vaccine has the potential to be used in developing immunity towards COVID-19 and other viruses.

Read More at: https://www.biospace.com/article/releases/auravax-therapeutics-enters-into-exclusive-license-agreement-with-the-university-of-houston-for-intranasal-vaccine-and-therapeutics-technology-platform/

 

Industry: Biotechnology

Capricor and Johns Hopkins University Sign Licensing Deal for COVID-19 Test Platform’s IP and Know-How

shot by IP News Shots / 6:40 pm on 02 February, 2021

Capricor Therapeutics Inc. has entered into a licensing deal for the intellectual property, data and know-how of a COVID-19 serology test platform from Johns Hopkins University. Capricor will work towards the clinical development of the novel imaging-based serology test platform for COVID-19.

Read More at: https://seekingalpha.com/news/3656663-capricor-signs-intellectual-property-license-for-covid-19-serology-test-platform

Industry: Biotechnology